In what situations, if any, would you recommend NALIRIFOX over FOLFIRINOX for first-line treatment of patients with unresectable pancreatic cancer?

Topics: Gastrointestinal Cancers • Medical Oncology • ASCO 2023

Given the recent update from the NAPOLI-3 trial presented at GI ASCO 2023, the two regimens appear to have similar OS.

Answer from: Medical Oncologist at Community Practice

Given the currently available information, I would not use NALIRIFOX instead of mFOLFIRINOX in any situation.My reasons for this are: mFOLFIRINOX has been the standard of care for the treatment of metastatic and unresectable pancreatic cancer in patients who can tolerate this regimen for over a dec...

Comments

Medical Oncologist at Community Hospital
Do you feel there is a difference in the toxicity ...

Medical Oncologist
The only difference is the reduced neurotoxicity a...

Medical Oncologist

This question relates to "unresectable" pancreas cancer. The NAPOLI-3 trial included previously untreated patients with metastatic cancer. At a median follow-up of 16.1 months, median overall survival was 11.1 months with Nalirifox compared to 9.2 months with nab-paclitaxel and gemcitabine. However,...

Related Questions